Cue Biopharma Inc expected to post a loss of 38  cents a share - Earnings Preview

Cue Biopharma

11/03/2022 20:04

* Cue Biopharma Inc  CUE.OQ   CUE.O  is expected to show a
rise in
quarterly revenue when it reports  results on March 14
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 524.0% increase in revenue to $2.966 million from $475.33
thousand a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Cue Biopharma Inc
is for
a loss of 38 cents per share. For the same quarter last year,
the company reported a loss of 36 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cue
Biopharma Inc
is $30​, above​ its last closing price of $4.96. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.38       -0.39      -0.41     Missed  -5.1
 Jun. 30 2021  -0.41       -0.42      -0.33     Beat    20.7
 Mar. 31 2021  -0.38       -0.38      -0.41     Missed  -8.5​
 Dec. 31 2020  -0.35       -0.35      -0.36     Missed  -2.9
 ​​Sep.        -0.39       -0.38      -0.34     Beat    11.5
 30 2020                                                
 Jun. 30 2020  -0.44       -0.43      -0.38     Beat    10.8​
 Mar. 31 2020  -0.35       -0.35      -0.48     Missed  -37.1
 Dec. 31 2019  -0.42       -0.45      -0.36     Beat    19.6
 This summary was machine generated March 11 at 20:04 GMT.  All
figures in US dollars  unless otherwise stated